Cost-effectiveness of vasopressin in the treatment of septic shock: insights from a European societal perspective
Second-line VA is a cost-effective intervention for septic shock, notably when initiated early. These findings support guideline recommendations for early vasopressor use and emphasize the clinical and economic value of timely VA therapy.
Authors
- Federico Ghinelli
- Evelyn Walter
- Romain Pirracchio
- Marc Léone
- Isabelle Goyer
Institutions
- San Francisco General Hospital (US)
- Aix-Marseille Université (FR)
- Assistance Publique Hôpitaux de Marseille (FR)
- Orphagen Pharmaceuticals (United States) (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Institute for Pharmaeconomic Research (AT)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1080/13696998.2026.2622854
- Primary Topic
- Sepsis Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00